세계의 인터류킨 억제제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Interleukin Inhibitors Market is presumed to reach the market size of nearly USD 263.1 Billion by 2032 from USD 59.5 Billion in 2023 with a CAGR of 17.96% under the study period 2024-2032.

Interleukin inhibitors refer to the immunosuppressive agents that can inhibit the interleukin's actions. Interleukins are a group of cytokines synthesized by white blood cells. They play a vital role in immune system regulation. Interleukin inhibitors are utilized to treat various autoimmune and inflammatory diseases. Interleukin inhibitors work by targeting cytokines that act as chemical signals between the white blood cells against the response of invading infection. They subdue the activity of these cytokines, thus reducing inflammation and suppressing the immune system.

MARKET DYNAMICS

The rising prevalence of autoimmune diseases and increasing adoption of interleukin inhibitors is the major factor driving the interleukin inhibitors market. The growing preference for targeted therapies is increasing due to their improved safety and efficacy profiles, patent expiry, and increased adoption of a biosimilar in Tumor Necrosis Factor (TNF) into the augmented usage of oxytocic drugs, which leads to high market demand. The rising new product launches are one of the important growth rendering drivers; for instance, in 2019, AbbVie, Inc. had launched Skyrizi (risankizumab-rzaa) for the treatment of plaque psoriasis treatment is stimulating the high market demand in the forecast period. Moreover, label expansions of marketed products, such as actemra for juvenile idiopathic arthritis and dupixent for atopic dermatitis and favorable government initiatives, and increasing consumer awareness is likely to create lucrative growth opportunities for key players of the interleukin inhibitors market in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Interleukin Inhibitors. The growth and trends of Interleukin Inhibitors industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Interleukin Inhibitors market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Asthma
• Inflammatory Bowel Disease (IBD)
• Others

By Type

• IL-17
• IL-23
• IL-1
• IL-5
• IL-6
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Interleukin Inhibitors market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Interleukin Inhibitors market include Johnson & Johnson Services Inc., Novartis AG, AbbVie Inc., Eli Lilly And Company, Regeneron Pharmaceuticals Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc., Teva Pharmaceuticals Industries Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. INTERLEUKIN INHIBITORS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Application
  • 3.7.2 Market Attractiveness Analysis By Type
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY APPLICATION

• 5.1. Overview By Application
• 5.2. Historical and Forecast Data Analysis By Application
• 5.3. Psoriasis Historic and Forecast Sales By Regions
• 5.4. Psoriatic Arthritis Historic and Forecast Sales By Regions
• 5.5. Rheumatoid Arthritis Historic and Forecast Sales By Regions
• 5.6. Asthma Historic and Forecast Sales By Regions
• 5.7. Inflammatory Bowel Disease (IBD) Historic and Forecast Sales By Regions
• 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY TYPE

• 6.1. Overview By Type
• 6.2. Historical and Forecast Data Analysis By Type
• 6.3. IL-17 Historic and Forecast Sales By Regions
• 6.4. IL-23 Historic and Forecast Sales By Regions
• 6.5. IL-1 Historic and Forecast Sales By Regions
• 6.6. IL-5 Historic and Forecast Sales By Regions
• 6.7. IL-6 Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL INTERLEUKIN INHIBITORS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTERLEUKIN INHIBITORS COMPANIES

• 8.1. Interleukin Inhibitors Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF INTERLEUKIN INHIBITORS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Johnson & Johnson Services Inc.
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Novartis AG
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. AbbVie Inc.
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Eli Lilly And Company
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Regeneron Pharmaceuticals Inc.
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. AstraZeneca
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. Bausch Health
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. F. Hoffmann-La Roche Ltd
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. GlaxoSmithKline Plc.
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. Teva Pharmaceuticals Industries Ltd
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies